Human Health Risk Assessment of Non-Regulated Xenobiotics in Recycled Water: A Review

Human and Ecological Risk Assessment

Volumn 18, Issue 3, 2012, Pages 517-546

  Debroux, Jean François ^a   Soller, Jeffrey A ^b   Plumlee, Megan H ^a   Kennedy, Laura J ^a  

^a KENNEDY JENKS CONSULTANTS   (United States)

^b Soller Environmental   (United States)

Author keywords

endocrine disruptors; pharmaceuticals; reclaimed wastewater; reuse; soil aquifer treatment; trace organics

Indexed keywords

EID: 84861945525     PISSN: 10807039     EISSN: 15497860     Source Type: Journal    
DOI: 10.1080/10807039.2012.672883     Document Type: Review

References (118)

1. Aerni, H-R, Kobler, BRutishauser, B. 2004. Combined biological and chemical assessment of estrogenic activities in wastewater treatment plant effluents. Anal Bioanal Chem, 378(3): 688-96.
2. Andersen, H, Siegrist, HHalling-Sørensen, B. 2003. Fate of estrogens in a municipal sewage treatment plant. Environ Sci Technol, 37(18): 4021-6.
3. Anderson, P D. 2008. Technical Brief: Trace Organic Compounds and Implications for Wastewater Treatment, Alexandria, VA, USA: Water Environment Research Foundation, 04- WEM-6.
4. Anderson, P D, D'Aco, V JShanahan, P. 2004. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environ Sci Technol, 38(3): 838-49.
5. Ankley, G T, Brooks, B WHuggett, D B. 2007. Repeating history: Pharmaceuticals in the environment. Environ Sci Technol, 41(24): 8211-7.
6. Asano, T and Cotruvo, J. 2004. Groundwater recharge with reclaimed municipal wastewater: Health and regulatory considerations. Water Res, 38(8): 1941-51.
7. Ayers, R S and Westcot, D W. 1985. "Water Quality for Agriculture: FAO Irrigation and Drainage Paper, 29 rev. 1". Rome, Italy: Food and Agriculture Organization of the United Nations.
8. Barnes, K K, Kolpin, D WFurlong, E T. 2008. A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States-I) groundwater. Sci Total Environ, 402(2-3): 192-200.
9. Baronti, C, Curini, RD'Ascenzo, G. 2000. Monitoring natural and synthetic estrogens at activated sludge sewage treatment plants and in a receiving river water. Environ Sci Technol, 34(24): 5059-66.
10. Bellona, C, Drewes, J EOilker, G. 2008. Comparing nanofiltration and reverse osmosis for drinking water augmentation. AWWA Research Foundation and WateReuse Foundation (WRF-03-013). J Am Water Works Assoc, 100(9): 102-16.
11. Benotti, M J, Trenholm, R AVanderford, B J. 2009. Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. Environ Sci Technol, 43(3): 597-603.
12. Bolong, N, Ismail, A FSalim, M R. 2009. A review of the effects of emerging contaminants in wastewater and options for their removal. Desalination, 239(1-3): 229-46.
13. Braun, P, Moeder, M and Schrader, S. Trace analysis of technical nonylphenol, bisphenol A and 17[alpha]-ethinylestradiol in wastewater using solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr A, 988(1)41-51. et al. 2003.
14. Bruce, G M, Pleus, R C and Snyder, S A. 2010. Toxicological relevance of pharmaceuticals in drinking water. Environ Sci Technol, 44(14): 5619-26.
15. Brun, G L, Bernier, MLosier, R. 2006. Pharmaceutically active compounds in Atlantic Canadian sewage treatment plant effluents and receiving waters, and potential for environmental effects as measured by acute and chronic aquatic toxicity. Environ Toxicol Chem, 25(8): 2163-76.
16. Burkhardt-Holm, P. 2010. Endocrine disruptors and water quality: A state-of-the-art review. Internat J Wat Resour Devel, 26(3): 477-93.
17. Buser, H-R, Poiger, T and Müller, M D. 1999. Occurrence and environmental behavior of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater. Environ Sci Technol, 33(15): 2529-35.
18. CA SWRCB (California State Water Resources Control Board). 2002. "Municipal Wastewater Recycling Survey". Available at http://www.swrcb.ca.gov/water_issues/programs/grants_loans/water_recycling/munirec.shtml
19. CA SWRCB. 2009. "General Waste Discharge Requirements for Landscape Irrigation Uses of Municipal Recycled Water (General Permit), Water Quality Order 2009-0006-DWQ". California State Water Resources Control Board. Available at http://www.waterboards.ca.gov/board_decisions/adopted_orders/water_quality/wqo09.shtml
20. Céspedes, R, Petrovic, MRaldúa, D. 2004. Integrated procedure for determination of endocrine-disrupting activity in surface waters and sediments by use of the biological technique recombinant yeast assay and chemical analysis by LC-ESI-MS. Anal Bioanal Chem, 378(3): 697-708.
21. Christensen, F M. 1998. Pharmaceuticals in the environment-A human risk?. Regul Toxicol Pharmacol, 28(3): 212-21.
22. Clinton, T. 2007. Reclaimed Water Aquifer Storage and Recovery-Potential Changes in Water Quality, Alexandria, VA, USA: WRF-03-009. WateReuse Foundation.
23. Colborn, T, vom Saal, F S and Soto, A M. 1993. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Impact Assess Rev, 14(5-6): 469-89.
24. Colborn, T, Dumanoski, D and Myers, J P. 1996. Our Stolen Future, Are We Threatening Our Fertility, Intelligence, and Survival? A Scientific Detective Story Dutton, New York, USA
25. Conroy, O, Quanrud, D MEla, W P. 2005. Fate of wastewater effluent hER-agonists and hER-antagonists during soil aquifer treatment. Environ Sci Technol, 39(7): 2287-93.
26. Cooper, R and Olivieri, A. 1998. "Infectious disease concerns in wastewater reuse". In Wastewater Reclamation and Reuse, Water Quality Management Library Vol. 10, Edited by: Asano, T. Lancaster, PA, USA: Technomic.
27. Cordy, G, Durna, NBouwer, H. 2003. "Persistence of pharmaceuticals, pathogens, and other organic wastewater contaminants when wastewater is used for groundwater recharge". Proceedings of the 3rd International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water, March 19-21. Minneapolis, MN, USA
28. Cotruvo, J A, Bull, RCrook, J. 2010. Identifying Health Effects Concerns of the Water Reuse Industry and Prioritizing Research Needs for Nomination of Chemicals for Research to Appropriate National and International Agencies, Alexandria, VA, USA: WateReuse Foundation.
29. Crane, M, Watts, C and Boucard, T. 2006. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ, 367(1): 23-41.
30. Crook, J. 2005. "Irrigation of Parks, Playgrounds, and Schoolyards with Reclaimed Water: Extent and Safety. Report WRF-04-006". Alexandria, VA, USA: WateReuse Foundation.
31. Crook, J. 2010. Regulatory Aspects of Direct Potable Reuse in California (white paper), Fountain Valley, CA, USA: National Water Research Institute.
32. Crook, J, MacDonald, J and Trussell, R. 1999. Potable use of reclaimed water. J Am Water Works Assoc, 91(8): 40-9.
33. Cunningham, V L, Buzby, MHutchinson, T. 2006. Effects of human pharmaceuticals on aquatic life: Next steps. Environ Sci Technol, 40(11): 3456-62.
34. Cunningham, V L, Binks, S P and Olson, M J. 2009. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol, 53(1): 39-45.
35. Damstra, T, Barlow, SBergman, A. 2002. "Global Assessment of the State-of-the-Science of Endocrine Disruptors: An Assessment Prepared by an Expert Group on Behalf of the World Health Organization, the International Labour Organisation, and the United Nations Environment Programme". Geneva, Switzerland: World Health Organization.
36. Daughton, C G. 2005. "Emerging" chemicals as pollutants in the environment: A 21st century perspective. Renew Resour J,: 6-23.
37. Daughton, C G and Ternes, T A. 1999. Pharmaceuticals and personal care products in the environment: Agents of subtle change?. Environ Health Perspect, 107(SUPPL.): 6, 907-38.
38. Drewes, J E and Shore, L S. 2001. "Concerns about Pharmaceuticals in Water Reuse, Groundwater Recharge, and Animal Waste". In Pharmaceuticals and Care Products in the Environment, 206-28. Washington, DC, USA: ACS Symposium Series, 791. American Chemical Society.
39. Drewes, J E, Fox, P and Jekel, M. 2001. Occurrence of iodinated X-ray contrast media in domestic effluents and their fate during indirect potable reuse. J Environ Sci Health, Part A, 36(9): 1633-45.
40. Drewes, J E, Heberer, T and Reddersen, K. 2002. Fate of pharmaceuticals during indirect potable reuse. Water Sci Technol, 46(3): 73-80.
41. Drewes, J E, Hemming, JLadenburger, S J. 2005. An assessment of endocrine disrupting activity changes during wastewater treatment through the use of bioassays and chemical measurements. Water Environ Res, 77(1): 12-23.
42. Drewes, J E, Sedlak, DSnyder, S A. 2008. Development of Indicators and Surrogates for Chemical Contaminant Removal During Wastewater Treatment and Reclamation, Alexandria, VA, USA: WateReuse Foundation.
43. Drewes, J E, Dickenson, E and Snyder, S A. 2009. Contributions of Household Chemicals to Sewage and Their Relevance to Municipal Wastewater Systems and the Environment, Alexandria, VA, USA: Water Environment Research Foundation.
44. Dufour, A, Evans, OBehymer, T. 2006. Water ingestion during swimming activities in a pool: A pilot study. J Water Health, 4(4): 425-30.
45. Filali-Meknassi, Y, Tyagi, R DSurampalli, R Y. 2004. Endocrine-disrupting compounds in wastewater, sludge-treatment processes, and receiving waters: Overview. Pract Periodical of Haz, Toxic, and Radioactive Waste Mgmt, 8(1): 39-56.
46. Focazio, M J, Kolpin, D WBarnes, K K. 2008. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States-II) untreated drinking water sources. Sci Total Environ, 402(2-3): 201-16.
47. Frick, E A, Henderson, A KMoll, D M. 2001. "Presence of pharmaceuticals in wastewater effluent and drinking water, metropolitan Atlanta, Georgia, July-September 1999". Proceedings of the Georgia Water Resources Conference, p 282. Athens, GA, USA, March 26-27
48. Gross, B, Montgomery-Brown, JNaumann, A. 2004. Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent-dominated river and wetland. Environ Toxicol Chem, 23(9): 2074-83.
49. Grünheid, S and Jekel, M. 2004. "Behavior of trace pollutants during bank filtration and ground water recharge of wastewater-impacted surface waters". Proceedings of the 4th International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water. National Ground Water Association. Minneapolis, MN, USA. October 13-15
50. Gurr, C G and Reinhard, M. 2006. Harnessing natural attenuation of pharmaceuticals and hormones in rivers. Environ Sci Technol, 40(9): 2872-6.
51. Hamilton, A J, Stagnitti, FPremier, R. 2006. Quantitative microbial risk assessment models for consumption of raw vegetables irrigated with reclaimed water. Appl Environ Microbiol, 72(5): 3284-90.
52. Heberer, T. 2002a. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: A review of recent research data. Toxicol Lett, 131(1-2): 5-17.
53. Heberer, T. 2002b. Tracking persistent pharmaceutical residues from municipal sewage to drinking water. J Hydrology, 266(3-4): 175-89.
54. Hilton, M J and Thomas, K V. 2003. Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A, 1015(1-2): 129-41.
55. Hotchkiss, A K, Rider, C V and Blystone, C R. Fifteen years after "Wingspread"- environmental endocrine disrupters and human and wildlife health: Where we are today and where we need to go. Toxicol Sci, 105(2)235-59. et al. 2008.
56. Huang, Y-W, Twidwell, D L and Elrod, J C. 2003. Occurrence and effects of endocrine disrupting chemicals in the environment. Pract Periodical of Haz, Toxic, and Radioactive Waste Mgmt, 7(4): 241-52.
57. Hudson, G B, Beller, HGrayson, A. 2004. Transport and Fate of Endocrine Disrupting Compounds in Groundwater from Non-Potable Reuse of Municipal Wastewater, Berkeley, CA, USA: Lawrence Livermore National Laboratory: University of California.
58. Jobling, S and Sumpter, J P. 1993. Detergent components in sewage effluent are weakly oestrogenic to fish: An in vitro study using rainbow trout (Oncorhynchus mykiss) hepatocytes. Aquat Toxicol, 27(3-4): 361-72.
59. Jones-Lepp, T L, Sanchez, C AMoy, T. 2010. Method development and application to determine potential plant uptake of antibiotics and other drugs in irrigated crop production systems. J Agric Food Chem, 58(22): 11568-73.
60. Jones, O A, Lester, J N and Voulvoulis, N. 2005. Pharmaceuticals: A threat to drinking water?. Trends Biotechnol, 23(4): 163-7.
61. Kari, F G and Giger, W. 1995. Modeling the photochemical degradation of ethylenediaminetetraacetate in the River Glatt. Environ Sci Technol, 29(11): 2814-27.
62. Kennedy, L, Debroux, J and Millan, M. 2010. "WRRF 09-07 research update: Risk assessment study of PPCPs in recycled water to support public review". Presented at 25th Annual WateReuse Symposium. Washington, DC, USA. September 13
63. Kinney, C A, Furlong, E TWerner, S L. 2006. Presence and distribution of wastewater-derived pharmaceuticals in soil irrigated with reclaimed water. Environ Toxicol Chem, 25(2): 317-26.
64. Kiwa. 2004. Pharmaceuticals and Personal Care Products in the Water Cycle: An International Review, Report No. KWR 04.013. Nieuwegein, the Netherlands: Kiwa NV Water Research.
65. Kolpin, D W, Furlong, E TMeyer, M T. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol, 36(6): 1202-11.
66. Kümmerer, K. 2009. Antibiotics in the aquatic environment-A review-Part I. Chemosphere, 75(4): 417-34.
67. Ladenburger, S J, Drewes, J EHemming, J. 2005. "Endocrine disrupting activity changes in water reclamation systems". Proceedings of the 20th Annual WaterReuse Symposium, WaterReuse and Desalination: Mile High Opportunities, Denver, CO, USA. September 18-21
68. Lin, A. Y. and Reinhard, M. 2005. Photodegradation of common environmental pharmaceuticals and estrogens in river water. Environ Toxicol Chem, 24(6): 1303-9.
69. Lin, A Y, Plumlee, M H and Reinhard, M. 2006. Natural attenuation of pharmaceuticals and alkylphenol polyethoxylate metabolites during river transport: Photochemical and biological transformation. Environ Toxicol Chem, 25(6): 1458-64.
70. Loraine, G A and Pettigrove, M E. 2006. Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in southern California. Environ Sci Technol, 40(3): 687-95.
71. Mansell, J, Drewes, J and Rauch, T. 2004. Removal mechanisms of endocrine disrupting compounds (steroids) during soil aquifer treatment. Water Sci Technol, 50(2): 229-37.
72. Monteiro, S C and Boxall, A BA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol, 202: 53-154.
73. Montgomery-Brown, J and Reinhard, M. 2003. Occurrence and behavior of alkylphenol polyethoxylates in the environment. Environ Eng Sci, 20(5): 471-86.
74. Montgomery-Brown, J, Drewes, J EFox, P. 2003. Behavior of alkylphenol polyethoxylate metabolites during soil aquifer treatment. Water Res, 37(15): 3672-81.
75. Morrall, D, McAvoy, DSchatowitz, B. 2004. A field study of triclosan loss rates in river water (Cibolo Creek, TX). Chemosphere, 54(5): 653-60.
76. Nellor, M H, Soller, J ABruce, G M. 2009. "Development and Application of Tools to Assess and Understand the Relative Risks of Drugs and Other Chemicals in Indirect Potable Reuse Water (Draft). Report WRF 06-018 Task 2". Alexandria, VA, USA: WateReuse Foundation.
77. Nimrod, A C and Benson, W H. 1996. Environmental estrogenic effects of alkylphenol ethoxylates. Crit Rev Toxicol, 26(3): 335-64.
78. Ottoson, J and Stenström, T A. 2003. Faecal contamination of greywater and associated microbial risks. Water Res, 37(3): 645-55.
79. Petrovic, M, Solé, MLópez De Alda, M J. 2002. Endocrine disruptors in sewage treatment plants, receiving river waters, and sediments: Integration of chemical analysis and biological effects on feral carp. Environ Toxicol Chem, 21(10): 2146-56.
80. Petterson, S R, Ashbolt, N J and Sharma, A. 2001. Microbial risks from wastewater irrigation of salad crops: A screening-level risk assessment. Water Environ Res, 73(6): 667-72.
81. Plumlee, M H and Reinhard, M. 2007. Photochemical attenuation of N-nitrosodimethylamine (NDMA) and other nitrosamines in surface water. Environ Sci Technol, 41: 6170-6.
82. Quanrud, D M, Quast, KConroy, O. 2004. Estrogenic activity and volume fraction of waste water origin in monitoring wells along the Santa Cruz River, Arizona. Ground Water Monit Rem, 24(2): 86-93.
83. Reinhard, M, Debroux, J and Litwiller, E. 2000. "Organic Contaminant Behavior during Groundwater Recharge with Santa Ana River Water, Technical Report 323". CA, USA:. Department of Civil and Environmental Engineering, Stanford University, Stanford.
84. Rodriguez-Mozaz, S and Weinberg, H S. 2010. Meeting report: Pharmaceuticals in water-An interdisciplinary approach to a public health challenge. Environ Health Perspect, 118(7): 1016-1020.
85. Rose, J, Dickson, LFarrah, S. 1996. Removal of pathogenic and indicator microorganisms by a full-scale water reclamation facility. Water Res, 30(11): 2785-97.
86. Sakaji, R and Funamizu, N. 1998. "Microbial risk assessment and its role in the development of wastewater reclamation policy". In Wastewater Reclamation and Reuse, Water Quality Management Library Vol 10, Edited by: Asano, T. Lancaster, PA, USA: Technomic.
87. Schmidt, C K, Lange, F T and Brauch, H-J. 2004. "Assessing the impact of different redox conditions and residence times on the fate of organic micropollutants during riverbank filtration". Proceedings of the 4th International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water, October 13-15. National Ground Water Association, Minneapolis, MN, USA
88. Schulman, L J, Sargent, E VNaumann, B D. 2002. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess, 8(4): 657-80.
89. Schwab, B W, Hayes, E PFiori, J M. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol, 42(3): 296-312.
90. Scruggs, C, Hunter, GSnyder, E. 2005. EDCs in wastewater: What's the next step. Water Environ Technol, 17(3): 24-31.
91. Sharpe, R M and Irvine, D S. 2004. How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health?. Br Med J, 328(7437): 447-51.
92. Shenker, M, Harush, DBen-Ari, J. 2011. Uptake of carbamazepine by cucumber plants-A case study related to irrigation with reclaimed wastewater. Chemosphere, 82(6): 905-10.
93. Snyder, S A. 2003. Endocrine disruptors as water contaminants: Toxicological implications for humans and wildlife. Southwest Hydrol, 2(6): 14-16.
94. Snyder, S A. 2006. "Removal of wastewater-Derived contaminates during oxidation processes". Proceedings of the 10th Annual WateReuse Foundation Research Conference10th Annual WateReuse Foundation Research Conference, Phoenix, AZ, USA
95. Snyder, S A. 2008. Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water. Ozone: Sci Eng, 30(1): 65-9.
96. Snyder, S A and Benotti, M. 2010. Endocrine disruptors and pharmaceuticals: Implications for water sustainability. Water Sci Technol, 61(1): 145-54.
97. Snyder, S A, Vanderford, BPearson, R. 2003a. Analytical methods used to measure endocrine disrupting compounds in water. Pract Periodical of Haz, Toxic, and Radioactive Waste Mgmt, 7(4): 224-34.
98. Snyder, S A, Westerhoff, PYoon, Y. 2003b. Pharmaceuticals, personal care products, and endocrine disruptors in water: Implications for the water industry. Environ Eng Sci, 20(5): 449-69.
99. Snyder, S A, Leising, JWesterhoff, P. 2004. Biological and physical attenuation of endocrine disruptors and pharmaceuticals: Implications for water reuse. Ground Water Monit Rem, 24(2): 108-18.
100. Snyder, S A, Trenholm, R ASnyder, E M. 2008a. Toxicological relevance of EDCs and pharmaceuticals in drinking water, Denver, CO: AWWA Research Foundation and WateReuse Foundation. Report #3085.
101. Snyder, S A, Vanderford, B JDrewes, J. 2008b. State of knowledge of endocrine disruptors and pharmaceuticals in drinking water, Denver, CO: AWWA Research Foundation.
102. Snyder, S A, Stanford, B DBruce, G M. 2010. "Identifying Hormonally Active Compounds, Pharmaceuticals, and Personal Care Product Ingredients of Health Concern from Potential Presence in Water Intended for Indirect Potable Reuse. Report WRF-05-005". Alexandria, VA, USA: WateReuse Foundation.
103. Soller, J A, Seto, E and Olivieri, A W. 2007. "Microbial risk assessment interface tool, Final Project Report (Project 04-HHE-3)". Water Environment Research Foundation.
104. Sutton, R, Jackson, JWalker, B. 2007. Down the drain: Sources of hormone-disrupting chemicals in San Francisco Bay, Oakland, CA, USA: Environmental Working Group.
105. Takigami, H, Taniguchi, NMatsuda, T. 2000. The fate and behaviour of human estrogens in a night soil treatment process. Water Sci Technol, 42(7-8): 45-51.
106. Ternes, T A. 1998. Occurrence of drugs in German sewage treatment plants and rivers. Water Res, 32(11): 3245-60.
107. Tixier, C, Singer, H POellers, S. 2003. Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. Environ Sci Technol, 37(6): 1061-8.
108. USEPA (US Environmental Protection Agency). 1997. Exposure Factors Handbook (Final Report) EPA/600/P-95/002F a-c. Washington, DC, USA
109. USEPA. 2000. Estimated per Capita Water Ingestion in the United States EPA-822-R-00-008. Washington, DC, USA
110. USEPA. 2003. CSFII Analysis of Food Intake Distributions EPA-600-R-03-029. Washington, DC, USA
111. USEPA. 2010a. Drinking Water Contaminant Candidate List Washington, DC, USA Available at http://www.epa.gov/safewater/ccl/ccl3.html
112. USEPA. 2010b. Treating Contaminants of Emerging Concern: A Literature Review Database EPA-820-R-10-002. Washington, DC, USA
113. Vandenberg, L N, Maffini, M VSonnenschein, C. 2009. Bisphenol-A and the great divide: A review of controversies in the field of endocrine disruption. Endocr Rev, 30(1): 75-95.
114. van Ginneken, M and Oron, G. 2000. Risk assessment of consuming agricultural products irrigated with reclaimed wastewater: An exposure model. Water Resour Res, 36(9): 2691-9.
115. Webb, S, Ternes, TGibert, M. 2003. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett, 142(3): 157-67.
116. Williams, R. 2005. Human Pharmaceuticals: Assessing the Impacts On Aquatic Ecosystems, Pensacola, FL, USA: SETAC Press.
117. Williams, R J, Johnson, A CSmith, J JL. 2003. Steroid estrogens profiles along river stretches arising from sewage treatment works discharges. Environ Sci Technol, 37(9): 1744-50.
118. Wu, C, Spongberg, A LWitter, J D. 2010. Uptake of pharmaceutical and personal care products by soybean plants from soils applied with biosolids and irrigated with contaminated water. Environ Sci Technol, 44(16): 6157-61.